Clinical Trials · NCT01753856
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 69
- Start date
- Jan 2013
- Locations
- 6 sites, United States, Canada
- Primary endpoint
- Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies